Evgeniya M. Nepomnyashchaya
◽
Galina Andreevna Nerodo
◽
Anna Ardzha
◽
Inna Arnoldovna Novikova
◽
Elena Petrovna Ulianova
◽
...
e17038 Background: The purpose of the study was to analyze morphological and immunohistochemical changes in patients with ovarian serous carcinomas under the influence of chemoimmunotherapy. Methods: The study included patients aged 52-76 years with stage IIIC-IV ovarian cancer with ascites. The patients were divided into two groups according to the treatment received: group A – 22 patients receiving neoadjuvant chemoimmunotherapy, 500 000 IU interferon-gamma (ingaron) on the 1st day and 1 000 000 IU on days 2, 3 and 5, and chemotherapy (carboplatin AUC-6 and paclitaxel 175 mg/m2) on day 4; group B – 24 patients receiving neoadjuvant chemoimmunotherapy and the same regimen of intraperitoneal interferon-gamma. The patients in two groups were similar in terms of disease stages, health condition and age. All patients received further surgery. Immunohistochemical study was performed on paraffin sections for the standard morphological study using Ki-67 rabbit monoclonal antibodies (Thermo scientific) and P-53 mouse monoclonal antibodies (Cell Marque). UltraVision Quanto Detection System HRP DAB was used for visualization. Results: Chemoimmunotherapy plus intraperitoneal interferon-gamma resulted in grade III-IV pathomorphosis, decreased apoptosis index and proliferation activity (р53 – 19.3±2.5%; Ki-67 – 6.2±0.58%) in comparison with the group receiving intramuscular interferon-gamma (р53 –27.6±3.11%; Ki-67 – 16.2±3.09%). The group with chemotherapy and intramuscular interferon-gamma showed grade II pathomorphosis. Conclusions: The study showed that chemotherapy with intraperitoneal interferon-gamma administration, compared with intramuscular one, resulted in more enhanced morphological changes.
Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay.
